1. Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19/BNT162b2 vaccination
- Author
-
Markus Hoffmann, Alexandra Dopfer-Jablonka, Stefanie Willenzon, Ivan Odak, Christian Schultze-Florey, Berislav Bošnjak, Inga Ravens, Annika Heidemann, Reinhold Förster, Michaela Friedrichsen, Christiane Ritter, Stefan Pöhlmann, Gema Morillas Ramos, Georg M. N. Behrens, Thomas Krey, Jan Münch, Anika Janssen, Anne Cossmann, Anja Bubke, Joana Barros-Martins, Jasmin Ristenpart, Günter Bernhardt, George Ssebyatika, Swantje I. Hammerschmidt, Metodi V. Stankov, and CiiM, Zentrum für individualisierte Infektionsmedizin, Feodor-Lynen-Str.7, 30625 Hannover.
- Subjects
0301 basic medicine ,CD4-Positive T-Lymphocytes ,COVID-19 Vaccines ,T cells ,Immunization, Secondary ,Heterologous ,CD8-Positive T-Lymphocytes ,Brief Communication ,Antibodies, Viral ,General Biochemistry, Genetics and Molecular Biology ,Viral vector ,03 medical and health sciences ,0302 clinical medicine ,Immune system ,Medical research ,Immunogenicity, Vaccine ,Immunity ,ChAdOx1 nCoV-19 ,parasitic diseases ,Medicine ,Humans ,030212 general & internal medicine ,BNT162 Vaccine ,Vaccines ,B cells ,biology ,business.industry ,SARS-CoV-2 ,Immunogenicity ,Vaccination ,COVID-19 ,General Medicine ,Virology ,Antibodies, Neutralizing ,CD4 Lymphocyte Count ,030104 developmental biology ,Immunization ,Spike Glycoprotein, Coronavirus ,biology.protein ,Antibody ,business - Abstract
Currently approved viral vector-based and mRNA-based vaccine approaches against coronavirus disease 2019 (COVID-19) consider only homologous prime-boost vaccination. After reports of thromboembolic events, several European governments recommended using AstraZeneca’s ChAdOx1-nCov-19 (ChAd) only in individuals older than 60 years, leaving millions of already ChAd-primed individuals with the decision to receive either a second shot of ChAd or a heterologous boost with mRNA-based vaccines. However, such combinations have not been tested so far. We used Hannover Medical School’s COVID-19 Contact Study cohort of healthcare professionals to monitor ChAd-primed immune responses before and 3 weeks after booster with ChAd (n = 32) or BioNTech/Pfizer’s BNT162b2 (n = 55). Although both vaccines boosted prime-induced immunity, BNT162b2 induced significantly higher frequencies of spike-specific CD4+ and CD8+ T cells and, in particular, high titers of neutralizing antibodies against the B.1.1.7, B.1.351 and P.1 variants of concern of severe acute respiratory syndrome coronavirus 2., In a study of healthcare professionals previously vaccinated with ChAdOx-1 nCoV-19, booster vaccination with BNT162b2 elicited more neutralizing antibodies with greater breadth, as well as higher frequencies of virus-specific T cells, than ChAdOx-1 nCoV-19.
- Published
- 2021